Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update
Purpose of Review This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT). Recent Findings F...
Gespeichert in:
| Veröffentlicht in: | Current oncology reports 2024-05, Vol.26 (5), p.538-550 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 550 |
|---|---|
| container_issue | 5 |
| container_start_page | 538 |
| container_title | Current oncology reports |
| container_volume | 26 |
| creator | Di Franco, Martina Zanoni, Lucia Fortunati, Emilia Fanti, Stefano Ambrosini, Valentina |
| description | Purpose of Review
This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT).
Recent Findings
Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET. Different approaches have been proposed so far to improve the PRRT therapeutic index, encompassing re-treatment protocols, combinations with other therapies and novel indications. Molecular imaging holds a potential added value in characterizing disease biology and heterogeneity using different radiopharmaceuticals (e.g., SST and FDG) and may provide predictive and prognostic parameters. Response assessment criteria are still an unmet need and new theranostic pairs showed preliminary encouraging results.
Summary
PRRT for NET has become a paradigm of modern theranostics. PRRT holds a favorable toxicity profile, and it is associated with a prolonged time to progression, reduction of symptoms, and improved patients’ quality of life. In light of further optimization, different new strategies have been investigated, along with the development of new radiopharmaceuticals. |
| doi_str_mv | 10.1007/s11912-024-01526-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11063107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3034247195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-28bed37d337d55419f92a9ce5edf62ed535c001c1e5a2731eed3c9c2ebc5d2d73</originalsourceid><addsrcrecordid>eNp9kctOHDEQRa0oUXiEH2ARtZQNm06q_OgeZxMQIgkSAimCteWxa8Cox57Y3Uj5-3gYHiELFpZt1fEtlw5j-wifEaD_UhA18ha4bAEV71r1hm2jErLteKffrs9ctKLXsMV2SrkF4AAzeM-2xEzNUHZ6mx3-sj6kOLkheGoubyjbmMoYXGlCbM5pyomiTy6HSPWaVoMty_K1OYrN1crbkT6wdws7FNp72HfZ1feTy-Of7dnFj9Pjo7PWyV6NLZ_NyYvei7qUkqgXmlvtSJFfdJy8EsoBoENSlvcCqdJOO05zpzz3vdhl3za5q2m-JO8ojtkOZpXD0uY_JtlgXlZiuDHX6c4gQicQ1gkHDwk5_Z6ojGYZiqNhsJHSVIwAIbnsUauKfvoPvU1TjnW-SkmtpFRaV4pvKJdTKZkWT79BMGtDZmPIVEPm3pBZR3_8d46nJ49KKiA2QKmleE35ufcrsX8BI4mcdw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3049544599</pqid></control><display><type>article</type><title>Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Di Franco, Martina ; Zanoni, Lucia ; Fortunati, Emilia ; Fanti, Stefano ; Ambrosini, Valentina</creator><creatorcontrib>Di Franco, Martina ; Zanoni, Lucia ; Fortunati, Emilia ; Fanti, Stefano ; Ambrosini, Valentina</creatorcontrib><description>Purpose of Review
This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT).
Recent Findings
Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET. Different approaches have been proposed so far to improve the PRRT therapeutic index, encompassing re-treatment protocols, combinations with other therapies and novel indications. Molecular imaging holds a potential added value in characterizing disease biology and heterogeneity using different radiopharmaceuticals (e.g., SST and FDG) and may provide predictive and prognostic parameters. Response assessment criteria are still an unmet need and new theranostic pairs showed preliminary encouraging results.
Summary
PRRT for NET has become a paradigm of modern theranostics. PRRT holds a favorable toxicity profile, and it is associated with a prolonged time to progression, reduction of symptoms, and improved patients’ quality of life. In light of further optimization, different new strategies have been investigated, along with the development of new radiopharmaceuticals.</description><identifier>ISSN: 1523-3790</identifier><identifier>ISSN: 1534-6269</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-024-01526-5</identifier><identifier>PMID: 38581469</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Humans ; Medicine ; Medicine & Public Health ; Neuroendocrine tumors ; Neuroendocrine Tumors - diagnostic imaging ; Neuroendocrine Tumors - radiotherapy ; Octreotide - analogs & derivatives ; Octreotide - therapeutic use ; Oncology ; Organometallic Compounds ; Positron emission tomography ; Positron-Emission Tomography - methods ; Precision medicine ; Quality of life ; Radioisotopes - therapeutic use ; Radiopharmaceuticals - therapeutic use ; Receptors, Peptide - metabolism ; Receptors, Peptide - therapeutic use ; Review ; Somatostatin ; Theranostic Nanomedicine - methods ; Topical Collection on Neuroendocrine Neoplasms ; Toxicity</subject><ispartof>Current oncology reports, 2024-05, Vol.26 (5), p.538-550</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-28bed37d337d55419f92a9ce5edf62ed535c001c1e5a2731eed3c9c2ebc5d2d73</citedby><cites>FETCH-LOGICAL-c475t-28bed37d337d55419f92a9ce5edf62ed535c001c1e5a2731eed3c9c2ebc5d2d73</cites><orcidid>0000-0002-1729-9438</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11912-024-01526-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11912-024-01526-5$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38581469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Franco, Martina</creatorcontrib><creatorcontrib>Zanoni, Lucia</creatorcontrib><creatorcontrib>Fortunati, Emilia</creatorcontrib><creatorcontrib>Fanti, Stefano</creatorcontrib><creatorcontrib>Ambrosini, Valentina</creatorcontrib><title>Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>Purpose of Review
This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT).
Recent Findings
Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET. Different approaches have been proposed so far to improve the PRRT therapeutic index, encompassing re-treatment protocols, combinations with other therapies and novel indications. Molecular imaging holds a potential added value in characterizing disease biology and heterogeneity using different radiopharmaceuticals (e.g., SST and FDG) and may provide predictive and prognostic parameters. Response assessment criteria are still an unmet need and new theranostic pairs showed preliminary encouraging results.
Summary
PRRT for NET has become a paradigm of modern theranostics. PRRT holds a favorable toxicity profile, and it is associated with a prolonged time to progression, reduction of symptoms, and improved patients’ quality of life. In light of further optimization, different new strategies have been investigated, along with the development of new radiopharmaceuticals.</description><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - diagnostic imaging</subject><subject>Neuroendocrine Tumors - radiotherapy</subject><subject>Octreotide - analogs & derivatives</subject><subject>Octreotide - therapeutic use</subject><subject>Oncology</subject><subject>Organometallic Compounds</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Precision medicine</subject><subject>Quality of life</subject><subject>Radioisotopes - therapeutic use</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Receptors, Peptide - metabolism</subject><subject>Receptors, Peptide - therapeutic use</subject><subject>Review</subject><subject>Somatostatin</subject><subject>Theranostic Nanomedicine - methods</subject><subject>Topical Collection on Neuroendocrine Neoplasms</subject><subject>Toxicity</subject><issn>1523-3790</issn><issn>1534-6269</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kctOHDEQRa0oUXiEH2ARtZQNm06q_OgeZxMQIgkSAimCteWxa8Cox57Y3Uj5-3gYHiELFpZt1fEtlw5j-wifEaD_UhA18ha4bAEV71r1hm2jErLteKffrs9ctKLXsMV2SrkF4AAzeM-2xEzNUHZ6mx3-sj6kOLkheGoubyjbmMoYXGlCbM5pyomiTy6HSPWaVoMty_K1OYrN1crbkT6wdws7FNp72HfZ1feTy-Of7dnFj9Pjo7PWyV6NLZ_NyYvei7qUkqgXmlvtSJFfdJy8EsoBoENSlvcCqdJOO05zpzz3vdhl3za5q2m-JO8ojtkOZpXD0uY_JtlgXlZiuDHX6c4gQicQ1gkHDwk5_Z6ojGYZiqNhsJHSVIwAIbnsUauKfvoPvU1TjnW-SkmtpFRaV4pvKJdTKZkWT79BMGtDZmPIVEPm3pBZR3_8d46nJ49KKiA2QKmleE35ufcrsX8BI4mcdw</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Di Franco, Martina</creator><creator>Zanoni, Lucia</creator><creator>Fortunati, Emilia</creator><creator>Fanti, Stefano</creator><creator>Ambrosini, Valentina</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1729-9438</orcidid></search><sort><creationdate>20240501</creationdate><title>Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update</title><author>Di Franco, Martina ; Zanoni, Lucia ; Fortunati, Emilia ; Fanti, Stefano ; Ambrosini, Valentina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-28bed37d337d55419f92a9ce5edf62ed535c001c1e5a2731eed3c9c2ebc5d2d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - diagnostic imaging</topic><topic>Neuroendocrine Tumors - radiotherapy</topic><topic>Octreotide - analogs & derivatives</topic><topic>Octreotide - therapeutic use</topic><topic>Oncology</topic><topic>Organometallic Compounds</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Precision medicine</topic><topic>Quality of life</topic><topic>Radioisotopes - therapeutic use</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Receptors, Peptide - metabolism</topic><topic>Receptors, Peptide - therapeutic use</topic><topic>Review</topic><topic>Somatostatin</topic><topic>Theranostic Nanomedicine - methods</topic><topic>Topical Collection on Neuroendocrine Neoplasms</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Franco, Martina</creatorcontrib><creatorcontrib>Zanoni, Lucia</creatorcontrib><creatorcontrib>Fortunati, Emilia</creatorcontrib><creatorcontrib>Fanti, Stefano</creatorcontrib><creatorcontrib>Ambrosini, Valentina</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Franco, Martina</au><au>Zanoni, Lucia</au><au>Fortunati, Emilia</au><au>Fanti, Stefano</au><au>Ambrosini, Valentina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>26</volume><issue>5</issue><spage>538</spage><epage>550</epage><pages>538-550</pages><issn>1523-3790</issn><issn>1534-6269</issn><eissn>1534-6269</eissn><abstract>Purpose of Review
This paper aims to address the latest findings in neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of combined diagnosis with positron emission tomography (PET) and treatment with peptide receptor radionuclide therapy (PRRT).
Recent Findings
Following NETTER-1 trial, PRRT with [177Lu]Lu-DOTATATE was approved by FDA and EMA and is routinely employed in advanced G1 and G2 SST (somatostatin receptor)-expressing NET. Different approaches have been proposed so far to improve the PRRT therapeutic index, encompassing re-treatment protocols, combinations with other therapies and novel indications. Molecular imaging holds a potential added value in characterizing disease biology and heterogeneity using different radiopharmaceuticals (e.g., SST and FDG) and may provide predictive and prognostic parameters. Response assessment criteria are still an unmet need and new theranostic pairs showed preliminary encouraging results.
Summary
PRRT for NET has become a paradigm of modern theranostics. PRRT holds a favorable toxicity profile, and it is associated with a prolonged time to progression, reduction of symptoms, and improved patients’ quality of life. In light of further optimization, different new strategies have been investigated, along with the development of new radiopharmaceuticals.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38581469</pmid><doi>10.1007/s11912-024-01526-5</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-1729-9438</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2024-05, Vol.26 (5), p.538-550 |
| issn | 1523-3790 1534-6269 1534-6269 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11063107 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Humans Medicine Medicine & Public Health Neuroendocrine tumors Neuroendocrine Tumors - diagnostic imaging Neuroendocrine Tumors - radiotherapy Octreotide - analogs & derivatives Octreotide - therapeutic use Oncology Organometallic Compounds Positron emission tomography Positron-Emission Tomography - methods Precision medicine Quality of life Radioisotopes - therapeutic use Radiopharmaceuticals - therapeutic use Receptors, Peptide - metabolism Receptors, Peptide - therapeutic use Review Somatostatin Theranostic Nanomedicine - methods Topical Collection on Neuroendocrine Neoplasms Toxicity |
| title | Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A24%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radionuclide%20Theranostics%20in%20Neuroendocrine%20Neoplasms:%20An%20Update&rft.jtitle=Current%20oncology%20reports&rft.au=Di%20Franco,%20Martina&rft.date=2024-05-01&rft.volume=26&rft.issue=5&rft.spage=538&rft.epage=550&rft.pages=538-550&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-024-01526-5&rft_dat=%3Cproquest_pubme%3E3034247195%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3049544599&rft_id=info:pmid/38581469&rfr_iscdi=true |